References
- 1. Helfrich I, Singer B. Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. Cancers. 2019;11:356. https://doi.org/10.3390/cancers11030356.10.3390/cancers11030356
- 2. Davey MG, Miller N, McInerney NM. A Review of Epidemiology and Cancer Biology of Malignant Melanoma. Cureus; 2021. https://doi.org/10.7759/cureus.15087.10.7759/cureus.15087
- 3. Turcu G, Nedelcu RI, Ion DA, Brînzea A, Cioplea MD, 11Jilaveanu LB, et al. CEACAM1: Expression and Role in Melanocyte Transformation. Disease Markers. 2016;2016:1–8. https://doi.org/10.1155/2016/9406319.10.1155/2016/9406319
- 4. Dinehart MS, Dinehart SM, Sukpraprut-Braaten S, High WA. Immunohistochemistry utilization in the diagnosis of melanoma. Journal of Cutaneous Pathology. 2020;47:446–50. https://doi.org/10.1111/cup.13648.10.1111/cup.13648
- 5. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, et al. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. Clinical and Developmental Immunology. 2012;2012:1–8. https://doi.org/10.1155/2012/290536.10.1155/2012/290536
- 6. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, et al. Plasma Markers for Identifying Patients with Metastatic Melanoma. Clinical Cancer Research. 2011;17:2417–25. https://doi.org/10.1158/1078-0432.ccr-10-2402.10.1158/1078-0432.CCR-10-2402
- 7. de Wit NJW, van Muijen GNP, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology. 2004;44:517–41. https://doi.org/10.1111/j.1365-2559.2004.01860.x.10.1111/j.1365-2559.2004.01860.x
- 8. Torres-Cabala C, Li-Ning-Tapia E, Hwu W-J. Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. Archives of Medical Research. 2020;51:827–38. https://doi.org/10.1016/j.arcmed.2020.09.008.10.1016/j.arcmed.2020.09.008
- 9. Khatib N, Pe’er J, Ortenberg R, Schachter J, Frenkel S, Markel G, et al. Carcinoembryonic Antigen Cell Adhesion Molecule-1 (CEACAM1) in Posterior Uveal Melanoma: Correlation with Clinical and Histological Survival Markers. Investigative Opthalmology & Visual Science. 2011;52:9368. https://doi.org/10.1167/iovs.10-6006.10.1167/iovs.10-6006
- 10. Calinescu A, Turcu G, Nedelcu RI, Brinzea A, Hodorogea A, Antohe M, et al. On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies. Journal of Immunology Research. 2018;2018:1–8. https://doi.org/10.1155/2018/7169081.10.1155/2018/7169081
- 11. Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, et al. Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy. Journal of Immunology Research. 2015;2015:1–8. https://doi.org/10.1155/2015/902137.10.1155/2015/902137
- 12. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer and Metastasis Reviews. 2013;32:643–71. https://doi.org/10.1007/s10555-013-9444-6.10.1007/s10555-013-9444-6
- 13. Sapoznik S, Ortenberg R, Schachter J r, Markel G. CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target. Current Topics in Medicinal Chemistry. 2012;12:3–10. https://doi.org/10.2174/156802612798919259.10.2174/156802612798919259
- 14. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger A-M, et al. CEACAM1 Enhances Invasion and Migration of Melanocytic and Melanoma Cells. The American Journal of Pathology. 2004;165:1781–7. https://doi.org/10.1016/s0002-9440(10)63433-5.10.1016/S0002-9440(10)63433-5
- 15. Ullrich N, Heinemann A, Nilewski E, Scheffrahn I, Klode J, Scherag A, et al. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Research. 2015;75:1897–907. https://doi.org/10.1158/0008-5472.can-14-1752.10.1158/0008-5472.CAN-14-1752
- 16. Horst AK, Wagener C. CEA-Related CAMs. Handbook of Experimental Pharmacology. 2004:283–341. https://doi.org/10.1007/978-3-540-68170-0_10.10.1007/978-3-540-68170-0_10
- 17. Kilic N, Oliveira-Ferrer L, Wurmbach J-H, Loges S, Chalajour F, Vahid SN, et al. Pro-angiogenic Signaling by the Endothelial Presence of CEACAM1. Journal of Biological Chemistry. 2005;280:2361–9. https://doi.org/10.1074/jbc.m409407200.10.1074/jbc.M409407200
- 18. Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, et al. Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis. Cancer Research. 2013;73:6584–96. https://doi.org/10.1158/0008-5472.can-13-0123.10.1158/0008-5472.CAN-13-0123
- 19. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Current Opinion in Cell Biology. 2006;18:565–71. https://doi.org/10.1016/j.ceb.2006.08.008.10.1016/j.ceb.2006.08.008
- 20. Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, et al. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. Neoplasia. 2018;20:401–9. https://doi.org/10.1016/j.neo.2018.01.012.10.1016/j.neo.2018.01.012
- 21. Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G. SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget. 2016;7:30166–77. https://doi.org/10.18632/oncotarget.7379.10.18632/oncotarget.7379
- 22. Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomarkers in Medicine. 2013;7:23–35. https://doi.org/10.2217/bmm.12.110.10.2217/bmm.12.110